fullscreen

eFinder

eFinder

Home › Clinical Trial Results › Article

New weight-loss shot appears to outperform other obesity drugs on market

The Guardian · 🇬🇧 public United Kingdom · · 696 words · By Maya Yang
Clinical Trial Results Obesity Treatment Pharmaceutical Innovation
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Clinical Trial Results

A new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly announced Thursday.

Claims checked 17
Techniques found 1
Topics 3

Coverage spectrum

Coverage gap: Low Right coverage
Left20%
Center80%
Right0%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

A new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly announced Thursday.

Why it matters

The Indiana-based pharmaceutical company in a press statement said that retatrutide, a once-weekly triple hormone receptor agonist, led to an average weight loss of 70.3lbs (28.3%) over 80 weeks among participants receiving the 12mg dose, with 45.3% achieving…

Common ground

In Eli Lilly’s phase three trial, 2,339 adults who have obesity or are overweight, have at least one weight-related comorbidity, and have no diabetes were randomized to receive retatrutide in doses of 4mg, 9mg, 12mg, or a placebo.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

open_in_new Read the original article: https://www.theguardian.com/science/2026/may/21/weight-loss-shot-eli-lilly-glp-1

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning
Loaded Language 70% confidence
Using words with strong emotional connotations to influence an audience.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 17 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 7
info Single Source 5
cancel Disputed 2
check_circle Corroborated 1
verified Verified By Reference 1
help Insufficient Evidence 1
info
Claim 1: “patients on the 4mg dose lost 47.2lbs (19.0%)”
SINGLE SOURCE
The specific weight loss for the 4mg dose (47.2 lbs / 19.0%) is mentioned in The Guardian's reporting but not corroborated by other provided sources.
travel_explore
web search NEUTRAL — Over 80 weeks, participants receiving the highest doses achieved substantial weight loss, the company said. Patients taking 9mg and 12mg of retatrutide lost an average of 64.4lbs (25.9%) and 70.3lbs (…
https://www.theguardian.com/science/2026/may/21/weight-loss-…
travel_explore
web search NEUTRAL — Your expert guide to understanding Retatrutide dosage. Discover how it works and the importance of gradual dose increases.
https://www.joinvoy.com/blog/retatrutide-dosage-guide
travel_explore
web search NEUTRAL — Participants receiving retatrutide 12 mg achieved an average weight loss of 36.6 lbs, equivalent to 16.8% of body weight. No weight-loss plateau was observed with retatrutide, as participants continue…
https://www.drugs.com/history/retatrutide.html
schedule
Claim 2: “Other side effects included diarrhea which affected 25.2%, 34.1%, and 32.0% of patients across the three dose groups, versus 13.5% on placebo.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 3: “Vomiting also increased with dose escalation, occurring in up to one in four patients on the highest dose, compared with 4.8% in the placebo group.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
info
Claim 4: “In Eli Lilly’s phase three trial, 2,339 adults who have obesity or are overweight, have at least one weight-related comorbidity, and have no diabetes were randomized to receive retatrutide in doses of 4mg, 9mg, 12mg, or a placebo.”
SINGLE SOURCE
While sources confirm retatrutide is in Phase 3 trials (TRIUMPH-4) and targets obesity, the specific number of participants (2,339) and the exact randomization criteria provided in the claim are not explicitly confirmed in the provided evidence snippets.
travel_explore
web search NEUTRAL — Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist.
https://en.wikipedia.org/wiki/Retatrutide
travel_explore
web search NEUTRAL — Based on Eli Lilly’s trial, weight loss with retatrutide appears to exceed what has been typically possible with other weight-loss medications, including Eli Lilly’s own Zepbound and Novo Nordisk’s We…
https://www.theguardian.com/science/2026/may/21/weight-loss-…
travel_explore
web search NEUTRAL — Eli Lilly's retatrutide just delivered the strongest Phase 3 weight loss results yet seen: 28.7% average weight loss in 68 weeks, with notable improvements in knee osteoarthritis pain. This triple-ago…
https://metabolicweekly.com/articles/retatrutide-triumph4-ph…
schedule
Claim 5: “Upper respiratory tract infections were reported in 14.2% of patients receiving 4mg of retatrutide, 12.2% on 9mg, and 13.1% on 12mg, compared with 11.6% in the placebo group.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 6: “GLP-1 receptor agonists may offer benefits beyond weight loss, including preventing anxiety and depression from worsening, as well as reducing sickness-related absences from work by nearly half.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
cancel
Claim 7: “Patients taking 9mg and 12mg of retatrutide lost an average of 64.4lbs (25.9%) and 70.3lbs (28.3%), respectively.”
DISPUTED
The Guardian reports 64.4 lbs (25.9%) for 9mg and 70.3 lbs (28.3%) for 12mg. However, other sources reporting on the TRIUMPH-4 trial cite 28.7% (71.2 lbs) for the 12mg dose, and another source mentions 64.2 lbs (29.1 kg) for 9mg.
travel_explore
web search NEUTRAL — 64.2 lbs (29.1 kg) lost with Retatrutide 9 mg.A high proportion of participants taking Retatrutide achieved clinically meaningful weight loss: 25% or more weight loss: 47.7% to 58.6%.
https://www.drugs.com/retatrutide.html
travel_explore
web search NEUTRAL — In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks.
https://investingnews.com/lilly-s-triple-agonist-retatrutide…
travel_explore
web search NEUTRAL — In clinical trials, people lost up to 28.7% of their body weight after 68 weeks. That's significantly more than typically seen with current treatments like Wegovy or Mounjaro. But here's the catch: re…
https://www.joinvoy.com/blog/retatrutide-dosage-guide
check_circle
Claim 8: “On Zepbound, users can expect to lose an average of 15% to 20% of starting body weight over 72 weeks.”
CORROBORATED
The Guardian reports an average loss of 15% to 20% over 72 weeks, and another study mentioned in the search results reports a 20.2% loss over 72 weeks.
travel_explore
web search NEUTRAL — On Zepbound, users can expect to lose an average of 15% to 20% of starting body weight over 72 weeks.
https://www.theguardian.com/science/2026/may/21/weight-loss-…
travel_explore
web search NEUTRAL — Zepbound results build over time. See a realistic month-by-month timeline, when weight loss starts, and how much you can lose in 3, 6, and 12 months.
https://www.noom.com/blog/weight-management/zepbound-results…
travel_explore
web search NEUTRAL — Zepbound users lost 50 lbs on average while Wegovy users lost 33 pounds.According to the study, which was sponsored by Lilly, people using Zepbound lost 20.2% of their body weight over 72 weeks, while…
https://www.dailywire.com/news/weight-loss-wars-new-study-we…
schedule
Claim 9: “Constipation was reported by roughly one-quarter of treated patients compared with 10.9% of those receiving placebo.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
info
Claim 10: “On Wegovy, users can expect to lose an average of 14% to 19% of starting body weight gradually over 64 to 72 weeks.”
SINGLE SOURCE
The Guardian's reporting on Wegovy's 14-19% loss is the only source providing these specific percentages and timeframes in the provided evidence; other sources discuss Wegovy generally without these specific stats.
travel_explore
web search NEUTRAL — Learn about Wegovy® (semaglutide) injection 2.4 mg, 7.2 mg or tablets 25 mg for adults with obesity or overweight and see how it supports weight loss with guidance, dosing information, and savings res…
https://www.wegovy.com/
travel_explore
web search NEUTRAL — Mar 19, 2026 · Find patient medical information for Wegovy (semaglutide) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
https://www.webmd.com/drugs/wegovy-semaglutide
travel_explore
web search NEUTRAL — Apr 1, 2026 · Wegovy pill and injection for weight loss, reducing heart risks, and for MASH. Wegovy helps reduce appetite and promote lasting weight management.
https://www.drugs.com/wegovy.html
info
Claim 11: “45.3% achieving at least 30% weight loss [on the 12mg dose of retatrutide]”
SINGLE SOURCE
The specific figure of 45.3% achieving at least 30% weight loss is mentioned in The Guardian's report of a press statement, but not corroborated by other provided search results.
travel_explore
web search NEUTRAL — ...pharmaceutical company in a press statement said that retatrutide, a once-weekly triple hormone receptor agonist, led to an average weight loss of 70.3lbs (28.3%) over 80 weeks among participants r…
https://www.theguardian.com/science/2026/may/21/weight-loss-…
travel_explore
web search NEUTRAL — Participants receiving retatrutide 12 mg achieved an average weight loss of 36.6 lbs, equivalent to 16.8% of body weight. No weight-loss plateau was observed with retatrutide, as participants continue…
https://www.drugs.com/history/retatrutide.html
travel_explore
web search NEUTRAL — The 12mg dose produced the most weight loss (up to 28.7% of body weight after 68 weeks), whilst lower doses were also effective but produced less dramatic results. Once approved, the official recommen…
https://www.joinvoy.com/blog/retatrutide-dosage-guide
cancel
Claim 12: “Eli Lilly announced Thursday that retatrutide led to an average weight loss of 70.3lbs (28.3%) over 80 weeks among participants receiving the 12mg dose”
DISPUTED
There is a conflict between sources. The Guardian reports 70.3 lbs (28.3%) over 80 weeks, while other sources (TRIUMPH-4 trial reports) cite 71.2 lbs (28.7%) over 68 weeks. Drugs.com cites a much lower figure of 36.6 lbs (16.8%) for the 12mg dose in a different context/period.
travel_explore
web search NEUTRAL — Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs.
https://www.theguardian.com/science/2026/may/21/weight-loss-…
travel_explore
web search NEUTRAL — Participants taking the 12-milligram dose of retatrutide lost an average of 28.7 percent of their body weight, or 71.2 pounds.
https://www.nytimes.com/2025/12/11/health/eli-lilly-retatrut…
travel_explore
web search NEUTRAL — In the TRIUMPH-4 trial, participants with obesity and knee osteoarthritis taking the highest dose of retatrutide (12 mg) lost an average of 28.7% of their body weight, equivalent to 71.2 pounds, over …
https://ca.investing.com/news/stock-market-news/eli-lilly-st…
schedule
Claim 13: “Retatrutide also showed significant improvements from baseline in several cardiovascular risk factors including HDL cholesterol, triglycerides and systolic blood pressure”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 14: “Nausea was reported in 28.6% of participants receiving the 4mg dose, 38.4% on 9mg, and 42.4% on 12mg, compared with 14.8% in the placebo group.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
verified
Claim 15: “Retatrutide is a GLP-1, like Wegovy and Zepbound, and a GIP (glucose-dependent insulinotropic polypeptide), like Zepbound, but it also includes a hormone that none of the other weight loss drugs on the market have: glucagon”
VERIFIED BY REFERENCE
Wikipedia explicitly identifies retatrutide as a 'triple glucagon hormone receptor agonist', which confirms it targets GLP-1, GIP, and glucagon receptors.
help
Claim 16: “retatrudtide and Zepbound are injected once a week with the dose increasing incrementally over time.”
INSUFFICIENT EVIDENCE
No evidence was provided in the search results to confirm the administration schedule or dose titration for both drugs.
info
Claim 17: “65.3% of participants on the 12mg regimen reduced their BMI below 30 – the clinical cutoff for obesity – including 37.5% of individuals who began the trial with a BMI of 40 or higher.”
SINGLE SOURCE
The web search results for this claim returned information about a movie titled '65', which is completely irrelevant to the medical claim regarding BMI reduction.
travel_explore
web search NEUTRAL — 65 is a 2023 American science fiction film written and directed by Scott Beck and Bryan Woods. It stars Adam Driver as an ancient astronaut who crashes on an unknown planet with a challenging environm…
https://en.wikipedia.org/wiki/65_(film)
travel_explore
web search NEUTRAL — 65: Directed by Scott Beck, Bryan Woods. With Adam Driver, Ariana Greenblatt, Chloe Coleman, Nika King. An astronaut crash lands on a mysterious planet only to discover he's not alone.
https://www.imdb.com/title/tt12261776/
travel_explore
web search NEUTRAL — Dec 14, 2022 · From the writers of A Quiet Place and producer Sam Raimi, #65movie is coming exclusively to movie theaters this March.Visit our site: https://www.65.movieFol...
https://www.youtube.com/watch?v=bHXejJq5vr0
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.